ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 10, 2012--
InSite Vision Incorporated (OTCBB:INSV) today announced that Chief
Executive Officer Timothy Ruane will speak at the 7th Annual
JMP Securities Healthcare Conference on Thursday, July 12, 2012 at 10:30
am Eastern at the Peninsula Hotel New York in New York, NY.
About InSite Vision
InSite Vision is advancing new and superior ophthalmologic products for
unmet eye care needs. The company’s product portfolio utilizes InSite
Vision’s proven DuraSite® bioadhesive polymer core
technology, an innovative platform that extends the duration of drug
retention on the surface of the eye, thereby reducing frequency of
treatment and improving the efficacy of topically delivered drugs. The
DuraSite platform is currently leveraged in two commercial products for
the treatment of bacterial eye infections, AzaSite®
(azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck,
and Besivance® (besifloxacin ophthalmic suspension) 0.6%,
marketed by Bausch + Lomb. InSite Vision’s clinical-stage ophthalmic
product pipeline includes AzaSite Plus™ and DexaSite™
for the treatment of eye infections, BromSite™ for pain and
swelling associated with ocular surgery, and ISV-101 for the treatment
of dry eye disease. For further information on InSite Vision, please
visit www.insitevision.com.
AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb
Incorporated.
Source: InSite Vision Incorporated
InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial
Officer
mail@insite.com
or
Media
and Investor inquiries
BCC Partners
Michelle Corral,
415-794-8662
Karen L. Bergman, 650-575-1509
View printer-friendly version